select a format

Single User License
USD 250 INR 16198
Site License
USD 500 INR 32395
Corporate User License
USD 750 INR 48593

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Pfizer Inc (PFE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Pfizer Inc (PFE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH32190D
  • |
  • Pages: 548
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Pfizer Inc (Pfizer) is a biopharmaceutical company, which focuses on the discovery, development, manufacture and marketing of healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products in key therapeutic areas including internal medicine, cancer, vaccines, inflammation and immunology and rare diseases. It also provides sterile injectable pharmaceuticals, infusion systems, biosimilars, as well as active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells prescription pharmaceutical products through wholesalers, besides selling them directly to retailers, hospitals, clinics, government agencies and pharmacies. It sells consumer healthcare products through pharmacies, retail chains, distributors and grocery and convenience stores. The company provides its products in the US, Canada, Latin America, Asia, Japan, South Korea, New Zealand, Australia, Finland, Scandinavian countries, Africa, the Middle East and Turkey. Pfizer is headquartered in New York, the US.

Pfizer Inc (PFE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 12

List of Figures 19

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 20

Pfizer Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 21

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 22

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 23

Pfizer Inc, Medical Devices Deals, 2011 to YTD 2017 25

Pfizer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 27

Pfizer Inc, Pharmaceuticals & Healthcare, Deal Details 50

Asset Purchase 50

Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 50

Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 51

Bamboo Therapeutics Acquires Viral Gene Therapy Manufacturing Facility from University of North Carolina 52

Medivation Acquires Rights to Talazoparib from BioMarin Pharma 53

Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 54

Bamboo Therapeutics Acquires Rights to Canavan Disease Proposed Drug from Rowan University 55

Zoetis Acquires Animal Health Assets of Abbott for USD255 Million 56

Pfizer Acquires Portfolio of Vaccines from Baxter for USD635 Million 57

Hospira Healthcare Completes Acquisition of Manufacturing and R&D Facility from Orchid Chemicals & Pharma for USD218 Million 58

Pfizer Acquires Melanocortin Receptors from MRC Technology 59

Pfizer Plans To Sell Certain Ohthalmology R&D Assets 60

Pfizer Completes Acquisition Of Polocard From Polpharma For US$32 Million 61

Pfizer Exercises Option To Acquire Manufacturing Facility In Rouses Point From Akrimax 62

Pfizer Acquires Product Portfolio from Akorn-Strides 63

Venture Financing 64

Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 64

Rhythm Pharma Raises USD41 Million in Mezzanine Financing 65

Circle Pharma Raises Funds through Series A Preferred Stock Financing 67

Ixchelsis Raises Additional USD12 Million in Venture Financing 68

Vtesse Raises USD17 Million in Extended Series A Financing 69

Second Genome Raises USD8.4 Million in Extended Series B Financing 70

Morphic Therapeutics Raises USD51.5 Million in Series A Venture Financing 71

Storm Therapeutics Raises USD16 Million in Series A Venture Financing 72

Blade Therapeutics Raises USD45 Million in Series B Financing 72

Second Genome Raises USD42.6 Million in Series B Financing 74

Cydan Development Raises USD31 Million in Series A Financing 75

Metabomed Raises USD18 Million in Series A Venture Financing 76

Mission Therapeutics Raises USD85.7 Million in Financing Round 77

Biodesy Raises USD10 Million in Series B Financing 78

Lodo Therapeutics Raises USD17 Million in Series A Financing 79

Bamboo Therapeutics Raises USD49.5 Million in Venture Financing 81

NextCure Raises USD67 Million in Series A Financing 81

Petra Pharma Raises USD48 Million in Series A Financing 82

Cortexyme Raises USD15 Million in Series A Financing Round 84

Merus Raises USD46.4 Million in First Tranche of Series C Financing 85

Rhythm Metabolic Raises USD40 Million in Series A Financing Round 87

Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 88

Mirna Therapeutics Raises USD41.8 Million in Series D Financing 90

Nimbus Therapeutics Raises USD43 Million in Series B Financing 91

Mersana Therapeutics Raises USD35 Million in Series B Financing 92

Vtesse Raises USD25 Million in Series A Financing 93

CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 94

Ziarco Raises USD33 Million in Series B Venture Financing 95

Quartet Medicine Raises USD17 Million in Series A Venture Financing 97

Circle Pharma Raises Funds through Seed Financing 97

Epic Sciences Raises USD30 Million in Series C Venture Financing 98

NexImmune Raises USD3 Million in Venture Financing 99

Mission Therapeutics Raises US$32 Million In Series B Financing 100

Biodesy Raises US$15 Million In Series A Financing 101

Merus Raises US$42 Million In Extended Series B Financing 102

Cydan Raises US$26 Million In Venture Financing 104

Aquinox Pharma Raises US$18 Million In Series C Financing 105

Flexion Therapeutics Raises US$20 Million In Series B Financing 107

Rhythm Pharma Raises US$33 Million In Series B Financing 108

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 109

Epic Sciences Raises US$13 Million In Series B Financing 110

Ziarco Pharma Raises US$6 Million In First Tranche Of Series A financing 111

Mirna Therapeutics Raises US$34 Million In Series C Financing 112

Mersana Therapeutics Raises US$27 Million In Series A-1 Financing 114

InnoPharma Raises US$8 Million In Venture Financing 115

Flexion Therapeutics Raises Additional US$13 Million In Series A Financing 116

Celladon Raises Additional US$10 Million In Series D Financing 117

InnoPharma Secures US$15 Million In Series A Financing Round 119

Neuronetics Secures US$30 Million In Series E Financing 120

NextWave Pharma Secures US$45 Million In Series C Financing Round 122

TetraLogic Pharma Secures US$23 Million In Second Tranche Of Series C Financing 123

Private Equity 125

Bain Capital May Acquire Laboratorio Teuto Brasileiro 125

Kohlberg Kravis Completes Acquisition Of Capsugel From Pfizer 126

Partnerships 127

Pfizer Enters into Licensing Agreement with Scripps Research Institute 127

Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 128

EpiThany Enters into Agreement with Merck and Pfizer 129

VAXIMM Enters into Agreement with Merck and Pfizer 130

Domain Therapeutics Enters into Partnership with Pfizer 131

Pfizer Enters into Agreement with Washington University in St. Louis 132

Edelris Enters into Research Agreement with Pfizer 133

AbCellera Biologics Enters into Research Agreement with Pfizer 133

Pfizer Partners with NovaMedica 134

PegBio Partners with Pfizer 135

Pfizer Enters into Agreement with National Cancer Institute 135

Debiopharm Partners with Merck and Pfizer 136

Transgene Enters into Agreement with Merck and Pfizer 137

Circle Pharma Partners with Pfizer 138

Pfizer Partners with inVentiv Health 139

Fuji Yakuhin and Pfizer Enter into Co-Promotion Agreement 140

BioRap Technologies Enters into Co- Development Agreement with Pfizer 140

Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 141

Merck, Pfizer and Verastem Enter into Agreement 142

Pfizer Enters into Agreement with California Institute for Biomedical Research 143

Pfizer Enters into Research Agreement with Adaptive Biotech 144

Merck, Pfizer and Syndax Pharma Enter into Agreement 144

Heptares Therapeutics Enters into Agreement with Pfizer 145

Pfizer Enters into Agreement with Biovac Institute 146

Pfizer Enters into Agreement with Synthon 147

CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 148

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 149

Regimmune Enters into Research Agreement with JDRF and Pfizer 150

BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 151

HiFiBiO Enters into Research Agreement with Pfizer 152

Alzheimer Drug Discovery Enters into Research Agreement with CTI for Alzheimer's Disease Drugs 152

HemoShear Enters into Agreement with Pfizer 153

Spark Therapeutics Enters into Co-Development Agreement with Pfizer 154

Pfizer Enters into Co-Development Agreement with Merck 155

Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 156

Crohns & Colitis Foundation of America and Pfizer Enter into Agreement for Inflammatory Bowel Disease 157

Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 158

Pfizer Enters into Development Agreement with Cellectis 159

X-Chem Enters into Co-Development Agreement with Pfizer 160

KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 161

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 162

BioRestorative Therapies Enters into Research Agreement with Pfizer 163

Process Systems Enters Into Co-Development Agreement With Pfizer 164

Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 164

Octapharma Enters Into Co-Marketing Agreement With Pfizer 165

Protagen Enters Into Biomarker Discovery Agreement With Pfizer 166

Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 167

Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 168

Sanford-Burnham Medical Research Institute Enters Into Research Agreement With Pfizer 169

Karo Bio Extends Research Agreement With Pfizer For RORgamma Modulators 170

Pfizer Plans To Form Joint Ventures To Accelerate Drug Development 171

Cytomx Therapeutics Enters Into Co-Development Agreement With Pfizer For Oncology Drug Conjugates 172

Centers For Therapeutic Innovation Partners with UC San Francisco 173

Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 174

Anacor Pharma Enters Into Research Agreement With Bill & Melinda Gates Foundation 175

Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 176

KineMed Extends Research Agreement With Pfizer 177

OxOnc Development Enters Into Co-Development Agreement With Pfizer For Crizotinib 178

AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 179

Cystic Fibrosis Foundation Therapeutics Enters Into Research Agreement With Pfizer For Cystic Fibrosis Drugs 180

Apredica Enters Into Research Agreement With Pfizer 182

Mochida Pharma Enters Into Agreement With Hospira Japan To Distribute And Promote Oncology Products 182

Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 183

Visterra Enters Into Agreement With Pfizer To Discover Novel Antibodies 184

SFJ Pharma Enters Into Co-Development Agreement With Pfizer For Dacomitinib 185

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 186

Nodality Enters Into Agreement With Pfizer For Single Cell Network Profiling Technology 187

Pfizer Enters Into Co-Development Agreement With Harvard University 188

Cold Spring Harbor Labs Enters Into Research Agreement With Pfizer For New Cancer Therapies 189

Ildong Pharma Enters Into Co-Promotion Agreement With Pfizer Pharma For Generic Drugs 190

Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 190

Pfizer Enters into Co-Promotion Agreement with Specpharm 191

Pfizer Plans To Enter Into Co-Development Agreement With India-Based Pharma Company 192

Pfizer Enters Into Co-Marketing Agreement With Biologics For Inlyta 193

ICM Enters into Research Collaboration with Pfizer 194

KineMed Enters Into Co-Development Agreement With Pfizer 194

SFJ Pharma Enters Into Co-Development Agreement With Pfizer 195

CollPlant Enters Into Research Agreement With Pfizer For Orthopedic Product 196

Karo Bio Enters Into Research Agreement With Pfizer For RORgamma Modulators 197

Children's Hospital Boston Enters Into Research Agreement With Pfizer 198

Sanford-Burnham Medical Research Institute Enters Into Agreement With Pfizer 199

Pfizer Enters Into Research Agreement With Medco Health Solutions And United BioSource 200

deCODE genetics Enters Into Research Agreement With Pfizer 201

Exonhit Enters Into Research Agreement With Pfizer 202

Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 203

Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 204

Pfizer Announces Co-Development Agreement With University Of California, San Diego 205

Pfizer Amends Its Co-Promotion Agreement With Astellas Pharma 207

The University Of Queensland Enters Into Co-Development Agreement With Pfizer Australia 207

BioPontis Alliance Enters Into Co-Development Agreement With Pfizer 208

Pfizer Signs MOU To Form Joint Venture With Shanghai Pharma 209

Zacharon Pharma Enters Into Research Collaboration With Pfizer 210

Pfizer Enters Into Co-Promotion Agreement With Daiichi Sankyo For Benicar 211

Selventa Enters Into An Agreement With Pfizer 212

iOWH Enters Into Research Agreement With Anacor Pharma 213

Charles River Labs Enters Into Distribution Agreement With Pfizer 214

Philochem Enters into Discovery Agreement with Pfizer 215

Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 215

Pfizer Japan Enters Into Co-Promotion Agreement With Takeda Pharma 216

Pfizer Japan Extends Co-Promotion Agreement With Takeda Pharma 217

MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 218

Theraclone Sciences Enters Into Co-Development Agreement With Pfizer 220

Sutro Biopharma Enters Into Collaboration With Pfizer 221

Santaris Pharma Expands Its Collaboration With Pfizer 222

Licensing Agreements 223

Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 223

Pfizer Enters into Licensing Agreement with HitGen 224

Absorption Systems Enters into Licensing Agreement with Pfizer 225

Pfizer Enters into Licensing Agreement with BioInvent International 226

Pfizer Enters into Licensing Agreement with Ab Initio Biotherapeutics 227

Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 228

Pfizer Enters into Licensing Agreement with OncoImmune 228

Pfizer Enters into Option Agreement with AnTolRx 229

Pfizer Enters into Licensing Agreement with Western Oncolytics 230

Shire to Enter into Licensing Agreement with Pfizer 231

Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 231

Pfizer Enters into Licensing Agreement with WAVE Life Sciences 232

Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 233

Pfizer Enters into Licensing Agreement with 4D Molecular Therapeutics 234

Pfizer Enters into Licensing Agreement with KineMed 235

Pfizer Enters into Licensing Agreement with BioAtla 236

Pfizer Enters into Licensing Agreement Servier for UCART19 237

Pfizer Enters into Licensing Agreement with Evotec 238

Tris Pharma Enters into Licensing Agreement with Pfizer Consumer Healthcare 239

Trophogen Enters into Licensing Agreement with Zoetis 240

Clinigen Extends Licensing Agreement with Hospira for Foscavir 240

Genedata Enters into Licensing Agreement with Pfizer 241

Opko Health Enters into Licensing Agreement with Pfizer 242

Philogen Exercises Option for Licensing Agreement with Pfizer 243

Medivation Exercises Option for Licensing Agreement with CureTech for Pidilizumab 244

iTeos Therapeutics Enters into Licensing Agreement with Pfizer 246

Cellmid Enters into Option Agreement with Zoetis to License Anti-Midkine Antibodies 247

MedGenesis Therapeutix Enters into Licensing Agreement with Pfizer 248

Puma Biotech Amends Licensing Agreement with Pfizer for Neratinib 249

Absorption Systems Enters into Licensing Agreement with Pfizer 250

Tabuk Pharma Enters into Licensing Agreement with Pfizer 251

Pfizer Terminates Licensing Agreement with Saniona 251

Kissei Pharma Enters Into Licensing Agreement With Pfizer For KUX-1151 252

Champions Oncology Enters into Licensing Agreement with Pfizer 253

Orion And Hospira Extend Licensing Agreement For Precedex 254

IRICoR And University Of Montreal Enter Into Licensing Agreement With Pfizer 255

Gliknik Enters Into Licensing Agreement With Pfizer For GL-2045 256

Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 258

Harbour Antibodies Enters Into Licensing Agreement With Pfizer For Human Monoclonal Antibodies 259

Sequella Enters Into Licensing Agreement With Pfizer For Sutezolid 259

Bioventus Enters Into Licensing Agreement With Pfizer For Bone Morphogenetic Protein Portfolio 260

Abcam Enters Into Licensing Agreement With Pfizer 261

Pfizer Acquires King Pharma 405

Pfizer Inc - Key Competitors 408

Key Employees 409

Locations And Subsidiaries 411

Head Office 411

Other Locations & Subsidiaries 411

Recent Developments 438

Strategy And Business Planning 438

Mar 06, 2017: Pfizer Selects Turner & Townsend For Expansion Of Its Clinical Research Unit In Belgium 438

List of Figures

Pfizer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21

Pfizer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 22

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 23

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 24

Pfizer Inc, Medical Devices Deals, 2011 to YTD 2017 26

List of Tables

Pfizer Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21

Pfizer Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 22

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 23

Pfizer Inc, Deals By Therapy Area, 2011 to YTD 2017 24

Pfizer Inc, Medical Devices Deals, 2011 to YTD 2017 26

Pfizer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 28

Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 51

Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 52

Bamboo Therapeutics Acquires Viral Gene Therapy Manufacturing Facility from University of North Carolina 53

Medivation Acquires Rights to Talazoparib from BioMarin Pharma 54

Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 55

Bamboo Therapeutics Acquires Rights to Canavan Disease Proposed Drug from Rowan University 56

Zoetis Acquires Animal Health Assets of Abbott for USD255 Million 57

Pfizer Acquires Portfolio of Vaccines from Baxter for USD635 Million 58

Hospira Healthcare Completes Acquisition of Manufacturing and R&D Facility from Orchid Chemicals & Pharma for USD218 Million 59

Pfizer Acquires Melanocortin Receptors from MRC Technology 60

Pfizer Plans To Sell Certain Ohthalmology R&D Assets 61

Pfizer Completes Acquisition Of Polocard From Polpharma For US$32 Million 62

Pfizer Exercises Option To Acquire Manufacturing Facility In Rouses Point From Akrimax 63

Pfizer Acquires Product Portfolio from Akorn-Strides 64

Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 65

Rhythm Pharma Raises USD41 Million in Mezzanine Financing 66

Circle Pharma Raises Funds through Series A Preferred Stock Financing 68

Ixchelsis Raises Additional USD12 Million in Venture Financing 69

Vtesse Raises USD17 Million in Extended Series A Financing 70

Second Genome Raises USD8.4 Million in Extended Series B Financing 71

Morphic Therapeutics Raises USD51.5 Million in Series A Venture Financing 72

Storm Therapeutics Raises USD16 Million in Series A Venture Financing 73

Blade Therapeutics Raises USD45 Million in Series B Financing 73

Second Genome Raises USD42.6 Million in Series B Financing 75

Cydan Development Raises USD31 Million in Series A Financing 76

Metabomed Raises USD18 Million in Series A Venture Financing 77

Mission Therapeutics Raises USD85.7 Million in Financing Round 78

Biodesy Raises USD10 Million in Series B Financing 79

Lodo Therapeutics Raises USD17 Million in Series A Financing 80

Bamboo Therapeutics Raises USD49.5 Million in Venture Financing 82

NextCure Raises USD67 Million in Series A Financing 82

Petra Pharma Raises USD48 Million in Series A Financing 83

Cortexyme Raises USD15 Million in Series A Financing Round 85

Merus Raises USD46.4 Million in First Tranche of Series C Financing 86

Rhythm Metabolic Raises USD40 Million in Series A Financing Round 88

Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 89

Mirna Therapeutics Raises USD41.8 Million in Series D Financing 91

Nimbus Therapeutics Raises USD43 Million in Series B Financing 92

Mersana Therapeutics Raises USD35 Million in Series B Financing 93

Vtesse Raises USD25 Million in Series A Financing 94

CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 95

Ziarco Raises USD33 Million in Series B Venture Financing 96

Quartet Medicine Raises USD17 Million in Series A Venture Financing 98

Circle Pharma Raises Funds through Seed Financing 98

Epic Sciences Raises USD30 Million in Series C Venture Financing 99

NexImmune Raises USD3 Million in Venture Financing 100

Mission Therapeutics Raises US$32 Million In Series B Financing 101

Biodesy Raises US$15 Million In Series A Financing 102

Merus Raises US$42 Million In Extended Series B Financing 103

Cydan Raises US$26 Million In Venture Financing 105

Aquinox Pharma Raises US$18 Million In Series C Financing 106

Flexion Therapeutics Raises US$20 Million In Series B Financing 108

Rhythm Pharma Raises US$33 Million In Series B Financing 109

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 110

Epic Sciences Raises US$13 Million In Series B Financing 111

Ziarco Pharma Raises US$6 Million In First Tranche Of Series A financing 112

Mirna Therapeutics Raises US$34 Million In Series C Financing 113

Mersana Therapeutics Raises US$27 Million In Series A-1 Financing 115

InnoPharma Raises US$8 Million In Venture Financing 116

Flexion Therapeutics Raises Additional US$13 Million In Series A Financing 117

Celladon Raises Additional US$10 Million In Series D Financing 118

InnoPharma Secures US$15 Million In Series A Financing Round 120

Neuronetics Secures US$30 Million In Series E Financing 121

NextWave Pharma Secures US$45 Million In Series C Financing Round 123

TetraLogic Pharma Secures US$23 Million In Second Tranche Of Series C Financing 124

Bain Capital May Acquire Laboratorio Teuto Brasileiro 126

Kohlberg Kravis Completes Acquisition Of Capsugel From Pfizer 127

Pfizer Enters into Licensing Agreement with Scripps Research Institute 128

Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 129

EpiThany Enters into Agreement with Merck and Pfizer 130

VAXIMM Enters into Agreement with Merck and Pfizer 131

Domain Therapeutics Enters into Partnership with Pfizer 132

Pfizer Enters into Agreement with Washington University in St. Louis 133

Edelris Enters into Research Agreement with Pfizer 134

AbCellera Biologics Enters into Research Agreement with Pfizer 134

Pfizer Partners with NovaMedica 135

PegBio Partners with Pfizer 136

Pfizer Enters into Agreement with National Cancer Institute 136

Debiopharm Partners with Merck and Pfizer 137

Transgene Enters into Agreement with Merck and Pfizer 138

Circle Pharma Partners with Pfizer 139

Pfizer Partners with inVentiv Health 140

Fuji Yakuhin and Pfizer Enter into Co-Promotion Agreement 141

BioRap Technologies Enters into Co- Development Agreement with Pfizer 141

Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 142

Merck, Pfizer and Verastem Enter into Agreement 143

Pfizer Enters into Agreement with California Institute for Biomedical Research 144

Pfizer Enters into Research Agreement with Adaptive Biotech 145

Merck, Pfizer and Syndax Pharma Enter into Agreement 145

Heptares Therapeutics Enters into Agreement with Pfizer 146

Pfizer Enters into Agreement with Biovac Institute 147

Pfizer Enters into Agreement with Synthon 148

CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 149

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 150

Regimmune Enters into Research Agreement with JDRF and Pfizer 151

BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 152

HiFiBiO Enters into Research Agreement with Pfizer 153

Alzheimer Drug Discovery Enters into Research Agreement with CTI for Alzheimer's Disease Drugs 153

HemoShear Enters into Agreement with Pfizer 154

Spark Therapeutics Enters into Co-Development Agreement with Pfizer 155

Pfizer Enters into Co-Development Agreement with Merck 156

Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 157

Crohns & Colitis Foundation of America and Pfizer Enter into Agreement for Inflammatory Bowel Disease 158

Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 159

Pfizer Enters into Development Agreement with Cellectis 160

X-Chem Enters into Co-Development Agreement with Pfizer 161

KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 162

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 163

BioRestorative Therapies Enters into Research Agreement with Pfizer 164

Process Systems Enters Into Co-Development Agreement With Pfizer 165

Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 165

Octapharma Enters Into Co-Marketing Agreement With Pfizer 166

Protagen Enters Into Biomarker Discovery Agreement With Pfizer 167

Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 168

Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 169

Sanford-Burnham Medical Research Institute Enters Into Research Agreement With Pfizer 170

Karo Bio Extends Research Agreement With Pfizer For RORgamma Modulators 171

Pfizer Plans To Form Joint Ventures To Accelerate Drug Development 172

Cytomx Therapeutics Enters Into Co-Development Agreement With Pfizer For Oncology Drug Conjugates 173

Centers For Therapeutic Innovation Partners with UC San Francisco 174

Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 175

Anacor Pharma Enters Into Research Agreement With Bill & Melinda Gates Foundation 176

Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 177

KineMed Extends Research Agreement With Pfizer 178

OxOnc Development Enters Into Co-Development Agreement With Pfizer For Crizotinib 179

AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 180

Cystic Fibrosis Foundation Therapeutics Enters Into Research Agreement With Pfizer For Cystic Fibrosis Drugs 181

Apredica Enters Into Research Agreement With Pfizer 183

Mochida Pharma Enters Into Agreement With Hospira Japan To Distribute And Promote Oncology Products 183

Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 184

Visterra Enters Into Agreement With Pfizer To Discover Novel Antibodies 185

SFJ Pharma Enters Into Co-Development Agreement With Pfizer For Dacomitinib 186

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 187

Nodality Enters Into Agreement With Pfizer For Single Cell Network Profiling Technology 188

Pfizer Enters Into Co-Development Agreement With Harvard University 189

Cold Spring Harbor Labs Enters Into Research Agreement With Pfizer For New Cancer Therapies 190

Ildong Pharma Enters Into Co-Promotion Agreement With Pfizer Pharma For Generic Drugs 191

Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 191

Pfizer Enters into Co-Promotion Agreement with Specpharm 192

Pfizer Plans To Enter Into Co-Development Agreement With India-Based Pharma Company 193

Pfizer Enters Into Co-Marketing Agreement With Biologics For Inlyta 194

ICM Enters into Research Collaboration with Pfizer 195

KineMed Enters Into Co-Development Agreement With Pfizer 195

SFJ Pharma Enters Into Co-Development Agreement With Pfizer 196

CollPlant Enters Into Research Agreement With Pfizer For Orthopedic Product 197

Karo Bio Enters Into Research Agreement With Pfizer For RORgamma Modulators 198

Children's Hospital Boston Enters Into Research Agreement With Pfizer 199

Sanford-Burnham Medical Research Institute Enters Into Agreement With Pfizer 200

Pfizer Enters Into Research Agreement With Medco Health Solutions And United BioSource 201

deCODE genetics Enters Into Research Agreement With Pfizer 202

Exonhit Enters Into Research Agreement With Pfizer 203

Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 204

Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 205

Pfizer Announces Co-Development Agreement With University Of California, San Diego 206

Pfizer Amends Its Co-Promotion Agreement With Astellas Pharma 208

The University Of Queensland Enters Into Co-Development Agreement With Pfizer Australia 208

BioPontis Alliance Enters Into Co-Development Agreement With Pfizer 209

Pfizer Signs MOU To Form Joint Venture With Shanghai Pharma 210

Zacharon Pharma Enters Into Research Collaboration With Pfizer 211

Pfizer Enters Into Co-Promotion Agreement With Daiichi Sankyo For Benicar 212

Selventa Enters Into An Agreement With Pfizer 213

iOWH Enters Into Research Agreement With Anacor Pharma 214

Charles River Labs Enters Into Distribution Agreement With Pfizer 215

Philochem Enters into Discovery Agreement with Pfizer 216

Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 216

Pfizer Japan Enters Into Co-Promotion Agreement With Takeda Pharma 217

Pfizer Japan Extends Co-Promotion Agreement With Takeda Pharma 218

MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 219

Theraclone Sciences Enters Into Co-Development Agreement With Pfizer 221

Sutro Biopharma Enters Into Collaboration With Pfizer 222

Santaris Pharma Expands Its Collaboration With Pfizer 223

Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 224

Pfizer Enters into Licensing Agreement with HitGen 225

Absorption Systems Enters into Licensing Agreement with Pfizer 226

Pfizer Enters into Licensing Agreement with BioInvent International 227

Pfizer Enters into Licensing Agreement with Ab Initio Biotherapeutics 228

Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 229

Pfizer Enters into Licensing Agreement with OncoImmune 229

Pfizer Enters into Option Agreement with AnTolRx 230

Pfizer Enters into Licensing Agreement with Western Oncolytics 231

Shire to Enter into Licensing Agreement with Pfizer 232

Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 232

Pfizer Enters into Licensing Agreement with WAVE Life Sciences 233

Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 234

Pfizer Enters into Licensing Agreement with 4D Molecular Therapeutics 235

Pfizer Enters into Licensing Agreement with KineMed 236

Pfizer Enters into Licensing Agreement with BioAtla 237

Pfizer Enters into Licensing Agreement Servier for UCART19 238

Pfizer Enters into Licensing Agreement with Evotec 239

Tris Pharma Enters into Licensing Agreement with Pfizer Consumer Healthcare 240

Trophogen Enters into Licensing Agreement with Zoetis 241

Clinigen Extends Licensing Agreement with Hospira for Foscavir 241

Genedata Enters into Licensing Agreement with Pfizer 242

Opko Health Enters into Licensing Agreement with Pfizer 243

Philogen Exercises Option for Licensing Agreement with Pfizer 244

Medivation Exercises Option for Licensing Agreement with CureTech for Pidilizumab 245

iTeos Therapeutics Enters into Licensing Agreement with Pfizer 247

Cellmid Enters into Option Agreement with Zoetis to License Anti-Midkine Antibodies 248

MedGenesis Therapeutix Enters into Licensing Agreement with Pfizer 249

Puma Biotech Amends Licensing Agreement with Pfizer for Neratinib 250

Absorption Systems Enters into Licensing Agreement with Pfizer 251

Tabuk Pharma Enters into Licensing Agreement with Pfizer 252

Pfizer Terminates Licensing Agreement with Saniona 252

Kissei Pharma Enters Into Licensing Agreement With Pfizer For KUX-1151 253

Champions Oncology Enters into Licensing Agreement with Pfizer 254

Orion And Hospira Extend Licensing Agreement For Precedex 255

IRICoR And University Of Montreal Enter Into Licensing Agreement With Pfizer 256

Gliknik Enters Into Licensing Agreement With Pfizer For GL-2045 257

Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 259

Harbour Antibodies Enters Into Licensing Agreement With Pfizer For Human Monoclonal Antibodies 260

Sequella Enters Into Licensing Agreement With Pfizer For Sutezolid 260

Pfizer Acquires King Pharma 406

Pfizer Inc, Key Competitors 409

Pfizer Inc, Key Employees 410

Pfizer Inc, Subsidiaries 412

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Pfizer Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com